Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity

D. Aradi, Orsolya Rideg, András Vorobcsuk, T. Magyarlaki, Balázs Magyari, Attila Kónyi, Tünde Pintér, I. Horváth, A. Komócsi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background The GRAVITAS trial showed that 150mg clopidogrel did not improve outcome in patients with high on-clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA). Materials and methods Clopidogrel-naive stable angina patients before ad hoc percutaneous coronary intervention were recruited into a randomized, double-blind, placebo-controlled trial (NCT00638326). Twelve to 24h after the 600-mg loading dose of clopidogrel, ADP 5μM-stimulated maximal (AGGmax), late platelet aggregation (AGGlate) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-PRI) were evaluated. Patients with HPR (AGGmax≥34%) were randomly allocated to 75 or 150mg clopidogrel after 4weeks. After control platelet function measurements at day 28, 75mg clopidogrel was administered to all patients until 1year. Results The study was prematurely terminated at the stage of 200 enroled patients. Administration of 150mg clopidogrel significantly reduced platelet aggregation (AGGmax: 45·0±6·8 vs. 33·8±15·1, P

Original languageEnglish
Pages (from-to)384-392
Number of pages9
JournalEuropean Journal of Clinical Investigation
Volume42
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

clopidogrel
Platelets
Blood Platelets
Stable Angina
Platelet Aggregation
Agglomeration
Phosphorylation
Percutaneous Coronary Intervention
Adenosine Diphosphate

Keywords

  • Clopidogrel
  • High platelet reactivity
  • Outcome
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry
  • Biochemistry

Cite this

Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity. / Aradi, D.; Rideg, Orsolya; Vorobcsuk, András; Magyarlaki, T.; Magyari, Balázs; Kónyi, Attila; Pintér, Tünde; Horváth, I.; Komócsi, A.

In: European Journal of Clinical Investigation, Vol. 42, No. 4, 04.2012, p. 384-392.

Research output: Contribution to journalArticle

Aradi, D. ; Rideg, Orsolya ; Vorobcsuk, András ; Magyarlaki, T. ; Magyari, Balázs ; Kónyi, Attila ; Pintér, Tünde ; Horváth, I. ; Komócsi, A. / Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity. In: European Journal of Clinical Investigation. 2012 ; Vol. 42, No. 4. pp. 384-392.
@article{3267d4daaddd48438dfc70cb816e3038,
title = "Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity",
abstract = "Background The GRAVITAS trial showed that 150mg clopidogrel did not improve outcome in patients with high on-clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA). Materials and methods Clopidogrel-naive stable angina patients before ad hoc percutaneous coronary intervention were recruited into a randomized, double-blind, placebo-controlled trial (NCT00638326). Twelve to 24h after the 600-mg loading dose of clopidogrel, ADP 5μM-stimulated maximal (AGGmax), late platelet aggregation (AGGlate) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-PRI) were evaluated. Patients with HPR (AGGmax≥34{\%}) were randomly allocated to 75 or 150mg clopidogrel after 4weeks. After control platelet function measurements at day 28, 75mg clopidogrel was administered to all patients until 1year. Results The study was prematurely terminated at the stage of 200 enroled patients. Administration of 150mg clopidogrel significantly reduced platelet aggregation (AGGmax: 45·0±6·8 vs. 33·8±15·1, P",
keywords = "Clopidogrel, High platelet reactivity, Outcome, Percutaneous coronary intervention",
author = "D. Aradi and Orsolya Rideg and Andr{\'a}s Vorobcsuk and T. Magyarlaki and Bal{\'a}zs Magyari and Attila K{\'o}nyi and T{\"u}nde Pint{\'e}r and I. Horv{\'a}th and A. Kom{\'o}csi",
year = "2012",
month = "4",
doi = "10.1111/j.1365-2362.2011.02594.x",
language = "English",
volume = "42",
pages = "384--392",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity

AU - Aradi, D.

AU - Rideg, Orsolya

AU - Vorobcsuk, András

AU - Magyarlaki, T.

AU - Magyari, Balázs

AU - Kónyi, Attila

AU - Pintér, Tünde

AU - Horváth, I.

AU - Komócsi, A.

PY - 2012/4

Y1 - 2012/4

N2 - Background The GRAVITAS trial showed that 150mg clopidogrel did not improve outcome in patients with high on-clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA). Materials and methods Clopidogrel-naive stable angina patients before ad hoc percutaneous coronary intervention were recruited into a randomized, double-blind, placebo-controlled trial (NCT00638326). Twelve to 24h after the 600-mg loading dose of clopidogrel, ADP 5μM-stimulated maximal (AGGmax), late platelet aggregation (AGGlate) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-PRI) were evaluated. Patients with HPR (AGGmax≥34%) were randomly allocated to 75 or 150mg clopidogrel after 4weeks. After control platelet function measurements at day 28, 75mg clopidogrel was administered to all patients until 1year. Results The study was prematurely terminated at the stage of 200 enroled patients. Administration of 150mg clopidogrel significantly reduced platelet aggregation (AGGmax: 45·0±6·8 vs. 33·8±15·1, P

AB - Background The GRAVITAS trial showed that 150mg clopidogrel did not improve outcome in patients with high on-clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA). Materials and methods Clopidogrel-naive stable angina patients before ad hoc percutaneous coronary intervention were recruited into a randomized, double-blind, placebo-controlled trial (NCT00638326). Twelve to 24h after the 600-mg loading dose of clopidogrel, ADP 5μM-stimulated maximal (AGGmax), late platelet aggregation (AGGlate) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-PRI) were evaluated. Patients with HPR (AGGmax≥34%) were randomly allocated to 75 or 150mg clopidogrel after 4weeks. After control platelet function measurements at day 28, 75mg clopidogrel was administered to all patients until 1year. Results The study was prematurely terminated at the stage of 200 enroled patients. Administration of 150mg clopidogrel significantly reduced platelet aggregation (AGGmax: 45·0±6·8 vs. 33·8±15·1, P

KW - Clopidogrel

KW - High platelet reactivity

KW - Outcome

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84858280313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858280313&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2011.02594.x

DO - 10.1111/j.1365-2362.2011.02594.x

M3 - Article

C2 - 21902692

AN - SCOPUS:84858280313

VL - 42

SP - 384

EP - 392

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 4

ER -